Combination Therapy In Dyslipidemia

Name: Combination Therapy In Dyslipidemia
Brand: Springer Nature
SKU: 9783319204321
Availability: InStock

Best Price:
Buy Combination Therapy In Dyslipidemia for $79.99 at @ Link.springer.com
No coupon is required — this is the standard retail price.

Set a price drop alert to never miss an offer.

1 Offer Price Range: $79.99 - $79.99

BEST PRICE

Single Product Purchase

$79.99

@ Link.springer.com BUY Now

Price Comparison

Seller	Contact Seller	List Price	On Sale	Shipping	Best Promo	Final Price	Volume Discount	Financing	Availability	Seller's Page
BEST PRICE 1 Product Purchase @ Link.springer.com		$79.99	$79.99			$79.99		See Site	In stock	Visit Store

Product Details

Brand

Springer Nature

Manufacturer

N/A

Part Number

GTIN

9783319204321

Condition

New

Product Description

Comprising contributions from leading lipidologists from around the world, this book presents the latest and most comprehensive knowledge on the different options for combination therapy of dyslipidemia and includes discussion of future therapies that are currently in late stages of clinical evaluation. Dyslipidemia is a leading cause of cardiovascular morbidity and mortality and most patients with this condition fail to achieve adequate control of their serum lipid levels with monotherapy. However, recent US and European guideline recommendations, based on randomized, controlled trials, fail to discuss combination therapy options for patients with dyslipidemia. Statins remain the mainstay of drug therapy for hyperlipidemia and chapters in this book specifically examine the role of add-on therapy with different agents modulating the different lipid fractions in the blood, e.g. bile acid sequestrants, fibric acid derivatives (fibrates), omega-3 fatty acids (fish oils), inhibitors of Niemann-Pick C1 like 1 (NPC1L1) protein, cholesteryl ester transfer protein (CETP), apolipoprotein B-100 and microsomal triglyceride transfer protein (MTP) and the emerging proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. There is additional discussion of the role of non-drug therapy options such as nutraceuticals, functional foods and lipoprotein apheresis. The book also discusses the combination of antihypertensive drugs with lipid-lowering drugs in the management of cardiovascular risk in patents with dyslipidemia.

Available Colors

N/A

Available Sizes

N/A